Pharmacology and Therapeutic Effects of Psilocybin
DOI:
https://doi.org/10.54097/hset.v65i.11331Keywords:
Psilocybin, toxicity, pharmacology, therapeutic effect.Abstract
Psilocybin, a psychoactive alkaloid with hallucinogenic properties, exists in a variety of hallucinogenic mushrooms. As a study tool to imitate psychosis, psilocybin has aroused a lot of interest in the biological community due to its various possible therapeutic benefits. It is also a very popular and widely misused natural hallucinogens with distinct metabolism pathways and toxicity. In this paper, the metabolism and mechanism of psilocybin were summarized, and the toxicology and pharmacology of psilocybin were discussed in detail, and the positive effects of psilocybin on psychological illnesses like depression, addiction, anxiety, and obsessive-compulsive disorder were gathered and sorted out, and the drug's therapeutic potential for mental and psychological illnesses was systematically clarified. Understanding the mechanism and therapeutic ability of psilocybin is of great significance to its potential development. As a hallucinogenic agent with low toxicity and no side effects, its effective application in the treatment of psychological and mental diseases can provide new ideas for the treatment of various diseases.
Downloads
References
Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998; 9(17): 3897-902.
Agurell S, Nilsson JL. Biosynthesis of psilocybin. II. Incorporation of labelled tryptamine derivatives. Acta Chem Scand. 1968; 22(4): 1210-8.
Moreno FA, Wiegand CB, Taitano EK et al. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006; 67(11): 1735-40.
Krebs TS, Johansen PØ. Psychedelics and mental health: a population study. PLoS One. 2013; 8(8): e63972.
Hasler F, Bourquin D, Brenneisen R et al. Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man. J Pharm Biomed Anal. 2002; 30(2): 331-9.
Griffiths RR, Richards WA, McCann U et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006; 187(3): 268-83; discussion 284-92.
Riba J, Valle M, Urbano G et al. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther. 2003; 306(1): 73-83.
Brown RT, Nicholas CR, Cozzi NV et al. Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. Clin Pharmacokinet. 2017; 56(12): 1543-1554.
Martel JC, Gatti McArthur S. Dopamine Receptor Subtypes, Physiology and Pharmacology: New Ligands and Concepts in Schizophrenia. Front Pharmacol. 2020; 11: 1003.
Passie T, Seifert J, Schneider U et al. The pharmacology of psilocybin. Addict Biol. 2002; 7(4): 357-64.
Davis AK, Barrett FS, May DG et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021; 78(5): 481-489.
Carhart-Harris RL, Bolstridge M, Rucker J et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016; 3(7): 619-27.
Bates MLS, Trujillo KA. Use and abuse of dissociative and psychedelic drugs in adolescence. Pharmacol Biochem Behav. 2021; 203: 173129.
Gill H, Gill B, Chen-Li D et al. The emerging role of psilocybin and MDMA in the treatment of mental illness. Expert Rev Neurother. 2020; 20(12): 1263-1273.
Ross S, Bossis A, Guss J et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016; 30(12): 1165-1180.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
